A detailed history of Borer Denton & Associates, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Borer Denton & Associates, Inc. holds 58,229 shares of ABBV stock, worth $13.6 Million. This represents 4.45% of its overall portfolio holdings.

Number of Shares
58,229
Previous 57,984 0.42%
Holding current value
$13.6 Million
Previous $10.8 Billion 25.27%
% of portfolio
4.45%
Previous 3.74%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 15, 2025

BUY
$184.85 - $231.54 $45,288 - $56,727
245 Added 0.42%
58,229 $13.5 Billion
Q2 2025

Aug 14, 2025

SELL
$170.16 - $206.27 $4,254 - $5,156
-25 Reduced 0.04%
57,984 $10.8 Billion
Q1 2025

May 15, 2025

SELL
$169.2 - $216.66 $207,270 - $265,408
-1,225 Reduced 2.07%
58,009 $12.2 Billion
Q4 2024

Feb 11, 2025

BUY
$164.99 - $203.87 $151,790 - $187,560
920 Added 1.58%
59,234 $10.5 Billion
Q3 2024

Nov 12, 2024

BUY
$163.84 - $199.33 $230,195 - $280,058
1,405 Added 2.47%
58,314 $11.5 Billion
Q2 2024

Aug 13, 2024

SELL
$154.79 - $180.76 $278,622 - $325,368
-1,800 Reduced 3.07%
56,909 $9.76 Billion
Q1 2024

Apr 25, 2024

BUY
$159.82 - $182.1 $110,915 - $126,377
694 Added 1.2%
58,709 $10.7 Billion
Q1 2023

Oct 19, 2023

BUY
$144.61 - $166.54 $72,738 - $83,769
503 Added 0.87%
58,015 $9.25 Billion
Q4 2022

Oct 19, 2023

BUY
$138.31 - $165.87 $50,068 - $60,044
362 Added 0.63%
57,512 $9.29 Billion
Q3 2022

Oct 19, 2023

SELL
$134.21 - $153.93 $13,689 - $15,700
-102 Reduced 0.18%
57,150 $7.67 Billion
Q2 2022

Oct 19, 2023

SELL
$137.62 - $174.96 $13,762 - $17,496
-100 Reduced 0.17%
57,252 $8.77 Billion
Q1 2022

Oct 19, 2023

BUY
$131.98 - $163.75 $7.57 Million - $9.39 Million
57,352 New
57,352 $9.3 Billion

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $414B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Borer Denton & Associates, Inc. Portfolio

Follow Borer Denton & Associates, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Borer Denton & Associates, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Borer Denton & Associates, Inc. with notifications on news.